Cytomx Therapeutics, Inc.

Takara Bio USA, Inc.

Pionyr Immunotherapeutics, Inc.

Portsmouth Merger Sub Ii, LLC

Sayantan Mitra

Madan M Paidhungat

George G Jokhadze

Dylan L Daniel

Na Cai

Hsin Wang

Nicole G Lapuyade

Erwan Le Scolan

Hikmat Haizar Assi

Walter A Bogdanoff

Leonard G Presta

Linda Liang

Venkataraman Sriram

Joshua Pollack

Kara Mojica

Vladislava Juric

Linnea Haeggblom

Michel Streuli

Thomas Patrick Quinn

Nadine Jahchan

Xi Yang

Alexey Yevgenyevich Berezhnoy

Provided herein are anti-MARCO antibodies. Provided are also methods of generating and using anti-MARCO antibodies.

Anti-MARCO antibodies and uses thereof

Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the CM1 and the CM2 function as a substrate for a protease; the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.

Activatable cytokine constructs and related compositions and methods

Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first peptide mask (PM1), a third cleavable moiety (CM3), a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1, and the CM3 is positioned between the PM1 and CP1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.

Masked activatable interferon constructs

Spin columns that include a poly(acid) membrane separation matrix are provided. Also provided are kits that include the subject devices, as well as methods of using the devices, e.g., in sample preparation (such as protein purification) protocols.

Spin columns comprising poly(acid) membrane separation matrices, and methods of making and using the same

Growing community of inventors

Mountain View, CA, United States of America

Sayantan Mitra